Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Seiter, K; Liu, DL; Feldman, EJ; Siddiqui, AD; Hoang, A; Baskind, P; Kancherla, R; Ahmed, T
   Intravenous bolus topotecan in patients with myelodysplastic syndrome
   LEUKEMIA & LYMPHOMA
   
   K. Seiter et al., "Intravenous bolus topotecan in patients with myelodysplastic syndrome", LEUK LYMPH, 42(5), 2001, pp. 963-968
2. Takagi, T; Saotome, T
   Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma
   LEUKEMIA & LYMPHOMA
   
   T. Takagi e T. Saotome, "Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma", LEUK LYMPH, 42(4), 2001, pp. 577-586
3. Platzer, P; Thalhammer, T; Reznicek, G; Hamilton, G; Zhang, RW; Jager, W
   Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver
   INTERNATIONAL JOURNAL OF ONCOLOGY
   
   P. Platzer et al., "Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver", INT J ONCOL, 19(6), 2001, pp. 1287-1293
4. Oka, M; Fukuda, M; Fukuda, M; Kinoshita, A; Kuba, M; Ichiki, M; Rikimaru, T; Soda, H; Takatani, H; Narasaki, F; Nagashima, S; Nakamura, YI; Hayashi, N; Kohno, S
   Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer
   EUROPEAN JOURNAL OF CANCER
   
   M. Oka et al., "Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer", EUR J CANC, 37(11), 2001, pp. 1359-1365
5. Yamamoto, W; Verweij, J; de Bruijn, P; de Jonge, MJA; Takano, H; Nishiyama, M; Kurihara, M; Sparreboom, A
   Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
   ANTI-CANCER DRUGS
   
   W. Yamamoto et al., "Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells", ANTI-CANC D, 12(5), 2001, pp. 419-432
6. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
   Modulation of camptothecin analogs in the treatment of cancer: a review
   ANTI-CANCER DRUGS
   
   D.F.S. Kehrer et al., "Modulation of camptothecin analogs in the treatment of cancer: a review", ANTI-CANC D, 12(2), 2001, pp. 89-105
7. Demarquay, D; Huchet, M; Coulomb, H; Lesueur-Ginot, L; Lavergne, O; Kasprzyk, PG; Bailly, C; Camara, J; Bigg, DCH
   The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison
   ANTI-CANCER DRUGS
   
   D. Demarquay et al., "The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison", ANTI-CANC D, 12(1), 2001, pp. 9-19
8. Clarke-Pearson, DL; Van Le, L; Iveson, T; Whitney, CW; Hanjani, P; Kristensen, G; Malfetano, JH; Beckman, RA; Ross, GA; Lane, SR; DeWitte, MH; Fields, SZ
   Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
   JOURNAL OF CLINICAL ONCOLOGY
   
   D.L. Clarke-Pearson et al., "Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer", J CL ONCOL, 19(19), 2001, pp. 3967-3975
9. Pagano, L; Mele, L; Voso, MT; Chiusolo, P; Putzulu, R; Mazzotta, S; Leone, G
   The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia
   HAEMATOLOGICA
   
   L. Pagano et al., "The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia", HAEMATOLOG, 86(4), 2001, pp. 440-441
10. Das, B; Madhusudhan, P; Reddy, PV; Anitha, Y
    Natural camptothecins
    INDIAN JOURNAL OF CHEMISTRY SECTION B-ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY
    
    B. Das et al., "Natural camptothecins", I J CHEM B, 40(6), 2001, pp. 453-464
11. Lee, ST; Jang, JH; Suh, HC; Hahn, JS; Ko, YW; Min, YH
    Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome
    AMERICAN JOURNAL OF HEMATOLOGY
    
    S.T. Lee et al., "Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome", AM J HEMAT, 68(4), 2001, pp. 237-245
12. Herrington, JD; Figueroa, JA; Kirstein, MN; Zamboni, WC; Stewart, CF
    Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    J.D. Herrington et al., "Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction", CANC CHEMOT, 47(1), 2001, pp. 89-93
13. Rodriguez, M; Rose, PG
    Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer
    GYNECOLOGIC ONCOLOGY
    
    M. Rodriguez e P.G. Rose, "Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer", GYNECOL ONC, 83(2), 2001, pp. 257-262
14. Homesley, HD; Hall, DJ; Martin, DA; Lewandowski, GS; Vaccarello, L; Nahhas, WA; Suggs, CL; Penley, RG
    Dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients
    GYNECOLOGIC ONCOLOGY
    
    H.D. Homesley et al., "Dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients", GYNECOL ONC, 83(2), 2001, pp. 394-399
15. Fulzele, DP; Satdive, RK; Pol, BB
    Growth and production of camptothecin by cell suspension cultures of Nothapodytes foetida
    PLANTA MEDICA
    
    D.P. Fulzele et al., "Growth and production of camptothecin by cell suspension cultures of Nothapodytes foetida", PLANTA MED, 67(2), 2001, pp. 150-152
16. Eckardt, JR
    Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy
    ONCOLOGY
    
    J.R. Eckardt, "Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy", ONCOL-BASEL, 61, 2001, pp. 42-46
17. Pujol, JL; von Pawel, J; Tumolo, S; Martoni, A; Hearn, S; Fields, SZ; Ross, G
    Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer
    ONCOLOGY
    
    J.L. Pujol et al., "Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer", ONCOL-BASEL, 61, 2001, pp. 47-54
18. Bojarski, C; Gitter, AH; Bendfeldt, K; Mankertz, J; Schmitz, H; Wagner, S; Fromm, M; Schulzke, JD
    Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis
    JOURNAL OF PHYSIOLOGY-LONDON
    
    C. Bojarski et al., "Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis", J PHYSL LON, 535(2), 2001, pp. 541-552
19. Beltinger, C; Debatin, KM
    Murine models for experimental therapy of pediatric solid tumors with poorprognosis
    INTERNATIONAL JOURNAL OF CANCER
    
    C. Beltinger e K.M. Debatin, "Murine models for experimental therapy of pediatric solid tumors with poorprognosis", INT J CANC, 92(3), 2001, pp. 313-318
20. Kawabata, S; Oka, M; Shiozawa, K; Tsukamoto, K; Nakatomi, K; Soda, H; Fukuda, M; Ikegami, Y; Sugahara, K; Yamada, Y; Kamihira, S; Doyle, LA; Ross, DD; Kohno, S
    Breast cancer resistance protein directly confers SN-38 resistance of lungcancer cells
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    S. Kawabata et al., "Breast cancer resistance protein directly confers SN-38 resistance of lungcancer cells", BIOC BIOP R, 280(5), 2001, pp. 1216-1223
21. Loos, WJ; Kehrer, D; Brouwer, E; Verweij, J; de Bruijn, P; Hamilton, M; Gill, S; Nooter, K; Stoter, G; Sparreboom, A
    Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography
    JOURNAL OF CHROMATOGRAPHY B
    
    W.J. Loos et al., "Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography", J CHROMAT B, 738(1), 2000, pp. 155-163
22. Hudson, AT
    Patent focus on antiparasitic agents: May-October 1999
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    A.T. Hudson, "Patent focus on antiparasitic agents: May-October 1999", EXPERT OP T, 10(2), 2000, pp. 153-163
23. Dejosez, M; Ramp, U; Mahotka, C; Krieg, A; Walczak, H; Gabbert, HE; Gerharz, CD
    Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
    CELL DEATH AND DIFFERENTIATION
    
    M. Dejosez et al., "Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan", CELL DEAT D, 7(11), 2000, pp. 1127-1136
24. Boucaud, M; Pinguet, F; Poujol, S; Astre, C; Bressolle, F
    Sensitive high performance liquid chromatographic fluorescence determination of topotecan in human plasma and parotid saliva
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    
    M. Boucaud et al., "Sensitive high performance liquid chromatographic fluorescence determination of topotecan in human plasma and parotid saliva", J LIQ CHR R, 23(15), 2000, pp. 2373-2390
25. Emerson, DL; Bendele, R; Brown, E; Chiang, SM; Desjardins, JP; Dihel, LC; Gill, SC; Hamilton, M; LeRay, JD; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B; Luzzio, MJ; Baccanari, D
    Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan
    CLINICAL CANCER RESEARCH
    
    D.L. Emerson et al., "Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan", CLIN CANC R, 6(7), 2000, pp. 2903-2912
26. Gelderblom, H; Loos, WJ; Verweij, J; de Jonge, MJA; Sparreboom, A
    Topotecan lacks third space sequestration
    CLINICAL CANCER RESEARCH
    
    H. Gelderblom et al., "Topotecan lacks third space sequestration", CLIN CANC R, 6(4), 2000, pp. 1288-1292
27. Malik, IA
    An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    
    I.A. Malik, "An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country", INT J GYN C, 10(6), 2000, pp. 443-448
28. Cortes, J; Estey, E; Beran, M; O'Brien, S; Giles, F; Koller, C; Keating, M; Kantarjian, H
    Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    LEUKEMIA & LYMPHOMA
    
    J. Cortes et al., "Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia", LEUK LYMPH, 36(5-6), 2000, pp. 479-484
29. Jonsson, E; Dhar, S; Jonsson, B; Nygren, P; Graf, W; Larsson, R
    Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines
    EUROPEAN JOURNAL OF CANCER
    
    E. Jonsson et al., "Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines", EUR J CANC, 36(16), 2000, pp. 2120-2127
30. De Cesare, M; Zunino, F; Pace, S; Pisano, C; Pratesi, G
    Efficacy and toxicity profile of oral topotecan in a panel of human tumourxenografts
    EUROPEAN JOURNAL OF CANCER
    
    M. De Cesare et al., "Efficacy and toxicity profile of oral topotecan in a panel of human tumourxenografts", EUR J CANC, 36(12), 2000, pp. 1558-1564
31. Schellens, JHM; Malingre, MM; Kruijtzer, CMF; Bardelmeijer, HA; van Tellingen, O; Schinkel, AH; Beijnen, JH
    Modulation of oral bioavailability of anticancer drugs: from mouse to man
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    
    J.H.M. Schellens et al., "Modulation of oral bioavailability of anticancer drugs: from mouse to man", EUR J PH SC, 12(2), 2000, pp. 103-110
32. Beran, M
    Intensive chemotherapy for patients with high-risk myelodysplastic syndrome
    INTERNATIONAL JOURNAL OF HEMATOLOGY
    
    M. Beran, "Intensive chemotherapy for patients with high-risk myelodysplastic syndrome", INT J HEMAT, 72(2), 2000, pp. 139-150
33. Adams, DJ; Dewhirst, MW; Flowers, JL; Gamcsik, MP; Colvin, OM; Manikumar, G; Wani, MC; Wall, ME
    Camptothecin analogues with enhanced antitumor activity at acidic pH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    D.J. Adams et al., "Camptothecin analogues with enhanced antitumor activity at acidic pH", CANC CHEMOT, 46(4), 2000, pp. 263-271
34. Mans, DRA; Di Leone, L; Caldas, APF; Maino, M; Almeida, L; Cancela, AS; Grivicich, I; da Rocha, AB; Schwartsmann, G
    Cellular and clinical pharmacokinetic/pharmacodynamic basis for lack of efficacy of 21-day continuous topotecan in patients with untreated advanced adenocarcinoma of the pancreas
    TUMORI
    
    D.R.A. Mans et al., "Cellular and clinical pharmacokinetic/pharmacodynamic basis for lack of efficacy of 21-day continuous topotecan in patients with untreated advanced adenocarcinoma of the pancreas", TUMORI, 86(6), 2000, pp. 458-464
35. Asbury, RF; Lipsitz, S; Graham, D; Falkson, CI; Baez, L; Benson, AB
    Treatment of squamous cell esophageal cancer with topotecan - An Eastern Cooperative Oncology Group study (E2293)
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    R.F. Asbury et al., "Treatment of squamous cell esophageal cancer with topotecan - An Eastern Cooperative Oncology Group study (E2293)", AM J CL ONC, 23(1), 2000, pp. 45-46
36. Lee, JH; Ham, YA; Choi, SH; Im, EO; Jung, JH; Im, KS; Kim, DK; Xu, Y; Wang, MW; Kim, ND
    Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomesase I inhibitor
    ARCHIVES OF PHARMACAL RESEARCH
    
    J.H. Lee et al., "Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomesase I inhibitor", ARCH PH RES, 23(4), 2000, pp. 338-343
37. Hoelzer, D; Gokbuget, N
    New approaches to acute lymphoblastic leukemia in adults: Where do we go?
    SEMINARS IN ONCOLOGY
    
    D. Hoelzer e N. Gokbuget, "New approaches to acute lymphoblastic leukemia in adults: Where do we go?", SEMIN ONCOL, 27(5), 2000, pp. 540-559
38. Sugiyama, T; Yakushiji, M; Noda, K; Ikeda, M; Kudoh, R; Yajima, A; Tomoda, Y; Terashima, Y; Takeuchi, S; Hiura, M; Saji, F; Takahashi, T; Umesaki, N; Sato, S; Hatae, M; Ohashi, Y
    Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer
    ONCOLOGY
    
    T. Sugiyama et al., "Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer", ONCOL-BASEL, 58(1), 2000, pp. 31-37
39. Van Hattum, AH; Pinedo, HM; Schluper, HMM; Hausheer, FH; Boven, E
    New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
    INTERNATIONAL JOURNAL OF CANCER
    
    A.H. Van Hattum et al., "New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer", INT J CANC, 88(2), 2000, pp. 260-266
40. Lotz, JP; Lhomme, C; Pautier, P; Couteau, C; Gligorov, J; Alexandre, J; Selle, F; Izrael, V; Maraninchi, D; Viens, P
    High-dose chemotherapy in ovarian adenocarcinoma
    BULLETIN DU CANCER
    
    J.P. Lotz et al., "High-dose chemotherapy in ovarian adenocarcinoma", B CANCER, 87(1), 2000, pp. 63-69
41. Tsai, TH; Chen, YF; Chou, CJ; Chen, CF
    Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection
    JOURNAL OF CHROMATOGRAPHY A
    
    T.H. Tsai et al., "Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection", J CHROMAT A, 870(1-2), 2000, pp. 221-226
42. Gerrits, CJH; Schellens, JHM; Burris, H; Eckardt, JR; Planting, AST; van der Burg, MEL; Rodriguez, GI; Loos, WJ; van Beurden, V; Hudson, I; Von Hoff, DD; Verweij, J
    A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin)
    CLINICAL CANCER RESEARCH
    
    C.J.H. Gerrits et al., "A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin)", CLIN CANC R, 5(1), 1999, pp. 69-75
43. Matsui, SI; Endo, W; Wrzosek, C; Haridas, K; Seetharamulu, P; Hausheer, FH; Rustum, YM
    Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: Mechanisms and clinical implications
    EUROPEAN JOURNAL OF CANCER
    
    S.I. Matsui et al., "Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: Mechanisms and clinical implications", EUR J CANC, 35(6), 1999, pp. 984-993
44. Lee, DS; Lee, SH; Kwon, GS; Lee, HK; Woo, JH; Kim, JG; Hong, SD
    Inhibition of DNA topoisomerase I by dihydrotanshinone I, components of a medicinal herb Salvia miltiorrhiza bunge
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
    
    D.S. Lee et al., "Inhibition of DNA topoisomerase I by dihydrotanshinone I, components of a medicinal herb Salvia miltiorrhiza bunge", BIOS BIOT B, 63(8), 1999, pp. 1370-1373
45. Beran, M; Estey, E; O'Brien, S; Cortes, J; Koller, CA; Giles, FJ; Kornblau, S; Andreeff, M; Vey, N; Pierce, SR; Hayes, K; Wong, GC; Keating, M; Kantarjian, H
    Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
    JOURNAL OF CLINICAL ONCOLOGY
    
    M. Beran et al., "Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia", J CL ONCOL, 17(9), 1999, pp. 2819-2830
46. Zamboni, WC; Bowman, LC; Tan, M; Santana, VM; Houghton, PJ; Meyer, WH; Pratt, CB; Heideman, RL; Gajjar, AJ; Pappo, AS; Stewart, CF
    Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    W.C. Zamboni et al., "Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors", CANC CHEMOT, 43(6), 1999, pp. 454-460
47. Del Tacca, M; Di Paolo, A; Danesi, R
    Clinical and preclinical pharmacology of Topotecan
    TUMORI
    
    M. Del Tacca et al., "Clinical and preclinical pharmacology of Topotecan", TUMORI, 85(6), 1999, pp. S3-S11
48. Vey, N; Kantarjian, H; Beran, M; O'Brien, S; Cortes, J; Koller, C; Estey, E
    Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    INVESTIGATIONAL NEW DRUGS
    
    N. Vey et al., "Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study", INV NEW DR, 17(1), 1999, pp. 89-95
49. Rosoff, PM; Bayliff, S
    Successful clinical response to irinotecan in desmoplastic round blue celltumor
    MEDICAL AND PEDIATRIC ONCOLOGY
    
    P.M. Rosoff e S. Bayliff, "Successful clinical response to irinotecan in desmoplastic round blue celltumor", MED PED ONC, 33(5), 1999, pp. 500-503
50. Beran, M; Kantarjian, H
    Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    SEMINARS IN HEMATOLOGY
    
    M. Beran e H. Kantarjian, "Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia", SEM HEMATOL, 36(4), 1999, pp. 3-10
51. Burris, HA
    The evolving role of oral topotecan
    SEMINARS IN HEMATOLOGY
    
    H.A. Burris, "The evolving role of oral topotecan", SEM HEMATOL, 36(4), 1999, pp. 26-32
52. Yoon, Y; Kim, YO; Lim, NY; Jeon, WK; Sung, HJ
    Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis inHL60 human premyelocytic leukemia cell line
    PLANTA MEDICA
    
    Y. Yoon et al., "Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis inHL60 human premyelocytic leukemia cell line", PLANTA MED, 65(6), 1999, pp. 532-535
53. Ormrod, D; Spencer, CM
    Topotecan - A review of its efficacy in small cell lung cancer
    DRUGS
    
    D. Ormrod e C.M. Spencer, "Topotecan - A review of its efficacy in small cell lung cancer", DRUGS, 58(3), 1999, pp. 533-551
54. de Jonge, MJA; Verweij, J; Loos, WJ; Dallaire, BK; Sparreboom, A
    Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    M.J.A. de Jonge et al., "Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva", CLIN PHARM, 65(5), 1999, pp. 491-499
55. Herben, VMM; Rosing, H; Huinink, WWT; van Zomeren, DM; Batchelor, D; Doyle, E; Beusenberg, FD; Beijnen, JH; Schellens, JHM
    Oral topotecan: bioavailability and effect of food co-administration
    BRITISH JOURNAL OF CANCER
    
    V.M.M. Herben et al., "Oral topotecan: bioavailability and effect of food co-administration", BR J CANC, 80(9), 1999, pp. 1380-1386
56. CHOLLET DF; GOUMAZ L; RENARD A; MONTAY G; VERNILLET L; ARNERA V; MAZZO DJ
    SIMULTANEOUS DETERMINATION OF THE LACTONE AND CARBOXYLATE FORMS OF THE CAMPTOTHECIN DERIVATIVE CPT-11 AND ITS METABOLITE SN-38 IN PLASMA BYHIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    Journal of chromatography B. Biomedical sciences and applications
    
    D.F. Chollet et al., "SIMULTANEOUS DETERMINATION OF THE LACTONE AND CARBOXYLATE FORMS OF THE CAMPTOTHECIN DERIVATIVE CPT-11 AND ITS METABOLITE SN-38 IN PLASMA BYHIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY", Journal of chromatography B. Biomedical sciences and applications, 718(1), 1998, pp. 163-175
57. Beran, M; Estey, E; O'Brien, SM; Giles, FJ; Koller, CA; Kornblau, S; Keating, M; Kantarjian, HM
    Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia
    LEUKEMIA & LYMPHOMA
    
    M. Beran et al., "Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia", LEUK LYMPH, 31(5-6), 1998, pp. 521-531
58. SUKHANOVA A; GROKHOVSKY S; ZHUZE A; ROPER D; BRONSTEIN I
    HUMAN DNA-TOPOISOMERASE-I ACTIVITY IS AFFECTED BY BIS-NETROPSINS BINDING TO DNA MINOR-GROOVE
    Biochemistry and molecular biology international
    
    A. Sukhanova et al., "HUMAN DNA-TOPOISOMERASE-I ACTIVITY IS AFFECTED BY BIS-NETROPSINS BINDING TO DNA MINOR-GROOVE", Biochemistry and molecular biology international, 44(5), 1998, pp. 997-1010
59. ROSING H; VANZOMEREN DM; DOYLE E; BULT A; BEIJNEN JH
    O-GLUCURONIDATION, A NEWLY IDENTIFIED METABOLIC PATHWAY FOR TOPOTECANAND N-DESMETHYL TOPOTECAN
    Anti-cancer drugs
    
    H. Rosing et al., "O-GLUCURONIDATION, A NEWLY IDENTIFIED METABOLIC PATHWAY FOR TOPOTECANAND N-DESMETHYL TOPOTECAN", Anti-cancer drugs, 9(7), 1998, pp. 587-592
60. JANSS AJ; CNAAN A; ZHAO HQ; SHPILSKY A; LEVOW C; SUTTON L; PHILLIPS PC
    SYNERGISTIC CYTOTOXICITY OF TOPOISOMERASE-I INHIBITORS WITH ALKYLATING-AGENTS AND ETOPOSIDE IN HUMAN BRAIN-TUMOR CELL-LINES
    Anti-cancer drugs
    
    A.J. Janss et al., "SYNERGISTIC CYTOTOXICITY OF TOPOISOMERASE-I INHIBITORS WITH ALKYLATING-AGENTS AND ETOPOSIDE IN HUMAN BRAIN-TUMOR CELL-LINES", Anti-cancer drugs, 9(7), 1998, pp. 641-652
61. IZBICKA E; LAWRENCE R; RAYMOND E; ECKHARDT G; FAIRCLOTH G; JIMENO J; CLARK G; VONHOFF DD
    IN-VITRO ANTITUMOR-ACTIVITY OF THE NOVEL MARINE AGENT, ECTEINASCIDIN-743 (ET-743, NSC-648766) AGAINST HUMAN TUMORS EXPLANTED FROM PATIENTS
    Annals of oncology
    
    E. Izbicka et al., "IN-VITRO ANTITUMOR-ACTIVITY OF THE NOVEL MARINE AGENT, ECTEINASCIDIN-743 (ET-743, NSC-648766) AGAINST HUMAN TUMORS EXPLANTED FROM PATIENTS", Annals of oncology, 9(9), 1998, pp. 981-987
62. HOUGHTON PJ; STEWART CF; THOMPSON J; SANTANA VM; FURMAN WL; FRIEDMAN HS
    PRECLINICAL AND CLINICAL-RESULTS WITH IRINOTECAN - EXTENDING PRINCIPLES LEARNED IN MODEL SYSTEMS TO CLINICAL-TRIALS DESIGN
    Oncology
    
    P.J. Houghton et al., "PRECLINICAL AND CLINICAL-RESULTS WITH IRINOTECAN - EXTENDING PRINCIPLES LEARNED IN MODEL SYSTEMS TO CLINICAL-TRIALS DESIGN", Oncology, 12(8), 1998, pp. 84-93
63. ROSEN LS
    IRINOTECAN IN LYMPHOMA, LEUKEMIA, AND BREAST, PANCREATIC, OVARIAN, AND SMALL-CELL LUNG CANCERS
    Oncology
    
    L.S. Rosen, "IRINOTECAN IN LYMPHOMA, LEUKEMIA, AND BREAST, PANCREATIC, OVARIAN, AND SMALL-CELL LUNG CANCERS", Oncology, 12(8), 1998, pp. 103-109
64. KRAUT EH; CROWLEY JJ; WADE JL; LAUFMAN LR; ALSINA M; TAYLOR SA; SALMON SE
    EVALUATION OF TOPOTECAN IN RESISTANT AND RELAPSING MULTIPLE-MYELOMA -A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Journal of clinical oncology
    
    E.H. Kraut et al., "EVALUATION OF TOPOTECAN IN RESISTANT AND RELAPSING MULTIPLE-MYELOMA -A SOUTHWEST-ONCOLOGY-GROUP STUDY", Journal of clinical oncology, 16(2), 1998, pp. 589-592
65. Luck, HJ; Scholz, U; Petry, KU; Bohmer, G; Kuhnle, H
    Importance of topotecan in the therapy of ovarian carcinoma, today and tomorrow
    ONKOLOGIE
    
    H.J. Luck et al., "Importance of topotecan in the therapy of ovarian carcinoma, today and tomorrow", ONKOLOGIE, 21, 1998, pp. 6-9
66. Gatzemeier, U
    Hycamtin in the therapy of non-small-cell lung cancer
    ONKOLOGIE
    
    U. Gatzemeier, "Hycamtin in the therapy of non-small-cell lung cancer", ONKOLOGIE, 21, 1998, pp. 18-21
67. Stewart, CF; Gajjar, AJ; Heideman, RL; Houghton, PJ
    Penetration of topotecan into cerebrospinal fluid after intravenous injection
    ONKOLOGIE
    
    C.F. Stewart et al., "Penetration of topotecan into cerebrospinal fluid after intravenous injection", ONKOLOGIE, 21, 1998, pp. 22-24
68. Weihrauch, MR; Tesch, H
    Topotecan in haematologic malignancies
    ONKOLOGIE
    
    M.R. Weihrauch e H. Tesch, "Topotecan in haematologic malignancies", ONKOLOGIE, 21, 1998, pp. 28-31
69. IYER L; RATAIN MJ
    CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS
    Cancer chemotherapy and pharmacology
    
    L. Iyer e M.J. Ratain, "CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS", Cancer chemotherapy and pharmacology, 42, 1998, pp. 31-43
70. CHOI SH; TSUCHIDA Y; YANG HW
    ORAL VERSUS INTRAPERITONEAL ADMINISTRATION OF IRINOTECAN IN THE TREATMENT OF HUMAN NEUROBLASTOMA IN NUDE-MICE
    Cancer letters
    
    S.H. Choi et al., "ORAL VERSUS INTRAPERITONEAL ADMINISTRATION OF IRINOTECAN IN THE TREATMENT OF HUMAN NEUROBLASTOMA IN NUDE-MICE", Cancer letters, 124(1), 1998, pp. 15-21
71. CAMPISI C; ZAPPALA A; TERENZI S; RAVAIOLI M
    ADVANCED OVARIAN-CANCER - STATE-OF-THE-ART AND FUTURE OUTLOOK
    Tumori
    
    C. Campisi et al., "ADVANCED OVARIAN-CANCER - STATE-OF-THE-ART AND FUTURE OUTLOOK", Tumori, 84(3), 1998, pp. 1-22
72. Lee, HK; Lee, DS; Lim, J; Kim, JS; Im, KS; Jung, JH
    Topoisomerase I inhibitors from the Streptomyces sp. strain KM86-9B isolated from a marine sponge
    ARCHIVES OF PHARMACAL RESEARCH
    
    H.K. Lee et al., "Topoisomerase I inhibitors from the Streptomyces sp. strain KM86-9B isolated from a marine sponge", ARCH PH RES, 21(6), 1998, pp. 729-733
73. TAKIMOTO CH; WRIGHT J; ARBUCK SG
    CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS
    Biochimica et biophysica acta, N. Gene structure and expression
    
    C.H. Takimoto et al., "CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS", Biochimica et biophysica acta, N. Gene structure and expression, 1400(1-3), 1998, pp. 107-119
74. CHESON BD
    STANDARD AND LOW-DOSE CHEMOTHERAPY FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
    Leukemia research
    
    B.D. Cheson, "STANDARD AND LOW-DOSE CHEMOTHERAPY FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES", Leukemia research, 22, 1998, pp. 17-21
75. SIU LL; ROWINSKY EK
    A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS
    Drug safety
    
    L.L. Siu e E.K. Rowinsky, "A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS", Drug safety, 18(6), 1998, pp. 395-417
76. SEITER K
    INDUCTION OF APOPTOSIS BY TOPOTECAN - IMPLICATIONS FOR THE TREATMENT OF LEUKEMIA
    Seminars in hematology
    
    K. Seiter, "INDUCTION OF APOPTOSIS BY TOPOTECAN - IMPLICATIONS FOR THE TREATMENT OF LEUKEMIA", Seminars in hematology, 35(3), 1998, pp. 22-25
77. BERAN M; KANTARJIAN H
    TOPOTECAN IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
    Seminars in hematology
    
    M. Beran e H. Kantarjian, "TOPOTECAN IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES", Seminars in hematology, 35(3), 1998, pp. 26-31
78. WINTER S; WELLER M
    POTENTIATION OF CD95L-INDUCED APOPTOSIS OF HUMAN-MALIGNANT GLIOMA-CELLS BY TOPOTECAN INVOLVES INHIBITION OF RNA-SYNTHESIS BUT NOT CHANGES IN CD95 OR CD95L PROTEIN EXPRESSION
    The Journal of pharmacology and experimental therapeutics
    
    S. Winter e M. Weller, "POTENTIATION OF CD95L-INDUCED APOPTOSIS OF HUMAN-MALIGNANT GLIOMA-CELLS BY TOPOTECAN INVOLVES INHIBITION OF RNA-SYNTHESIS BUT NOT CHANGES IN CD95 OR CD95L PROTEIN EXPRESSION", The Journal of pharmacology and experimental therapeutics, 286(3), 1998, pp. 1374-1382
79. MOREAU P; ANIZON F; SANCELME M; PRUDHOMME M; BAILLY C; CARRASCO C; OLLIER M; SEVERE D; RIOU JF; FABBRO D; MEYER T; AUBERTIN AM
    SYNTHESES AND BIOLOGICAL EVALUATION OF INDOLOCARBAZOLES, ANALOGS OF REBECCAMYCIN, MODIFIED AT THE IMIDE HETEROCYCLE
    Journal of medicinal chemistry
    
    P. Moreau et al., "SYNTHESES AND BIOLOGICAL EVALUATION OF INDOLOCARBAZOLES, ANALOGS OF REBECCAMYCIN, MODIFIED AT THE IMIDE HETEROCYCLE", Journal of medicinal chemistry, 41(10), 1998, pp. 1631-1640
80. IYER L; KING CD; WHITINGTON PF; GREEN MD; ROY SK; TEPHLY TR; COFFMAN BL; RATAIN MJ
    GENETIC PREDISPOSITION TO THE METABOLISM OF IRINOTECAN (CPT-11) - ROLE OF URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE ISOFORM 1A1 IN THE GLUCURONIDATION OF ITS ACTIVE METABOLITE (SN-38) IN HUMAN LIVER-MICROSOMES
    The Journal of clinical investigation
    
    L. Iyer et al., "GENETIC PREDISPOSITION TO THE METABOLISM OF IRINOTECAN (CPT-11) - ROLE OF URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE ISOFORM 1A1 IN THE GLUCURONIDATION OF ITS ACTIVE METABOLITE (SN-38) IN HUMAN LIVER-MICROSOMES", The Journal of clinical investigation, 101(4), 1998, pp. 847-854
81. Dittrich, C
    Topotecan - A new approach in the treatment of ovarian cancer
    GEBURTSHILFE UND FRAUENHEILKUNDE
    
    C. Dittrich, "Topotecan - A new approach in the treatment of ovarian cancer", GEBURTSH FR, 58(12), 1998, pp. M185-M189
82. BROGDEN RN; WISEMAN LR
    TOPOTECAN - A REVIEW OF ITS POTENTIAL IN ADVANCED OVARIAN-CANCER
    Drugs
    
    R.N. Brogden e L.R. Wiseman, "TOPOTECAN - A REVIEW OF ITS POTENTIAL IN ADVANCED OVARIAN-CANCER", Drugs, 56(4), 1998, pp. 709-723
83. Boige, V; Raymond, E; Armand, JP
    Irinotecan: drug schedule, research of combinations, and phase I experiences
    BULLETIN DU CANCER
    
    V. Boige et al., "Irinotecan: drug schedule, research of combinations, and phase I experiences", B CANCER, 1998, pp. 26-32
84. PAZARES L; KUNKA R; DEMARIA D; CASSIDY J; ALDEN M; BERANEK P; KAYE S; LITTLEFIELD D; REILLY D; DEPEE S; WISSEL P; TWELVES C; ODWYER P
    A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION
    British Journal of Cancer
    
    L. Pazares et al., "A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION", British Journal of Cancer, 78(10), 1998, pp. 1329-1336
85. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; LUTZ L; LUO XL; LI YL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
    EFFICACY OF SYSTEMIC ADMINISTRATION OF IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS
    Clinical cancer research
    
    J. Thompson et al., "EFFICACY OF SYSTEMIC ADMINISTRATION OF IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS", Clinical cancer research, 3(3), 1997, pp. 423-431
86. IKEGAMI R; RIVERABENNETTS AK; BROOKER DL; YAGER TD
    EFFECT OF INHIBITORS OF DNA-REPLICATION ON EARLY ZEBRAFISH EMBRYOS - EVIDENCE FOR COORDINATE ACTIVATION OF MULTIPLE INTRINSIC CELL-CYCLE CHECKPOINTS AT THE MID-BLASTULA TRANSITION
    Zygote
    
    R. Ikegami et al., "EFFECT OF INHIBITORS OF DNA-REPLICATION ON EARLY ZEBRAFISH EMBRYOS - EVIDENCE FOR COORDINATE ACTIVATION OF MULTIPLE INTRINSIC CELL-CYCLE CHECKPOINTS AT THE MID-BLASTULA TRANSITION", Zygote, 5(2), 1997, pp. 153-175
87. LOPEZMEYER M; NESSLER CL
    TRYPTOPHAN DECARBOXYLASE IS ENCODED BY 2 AUTONOMOUSLY REGULATED GENESIN CAMPTOTHECA-ACUMINATA WHICH ARE DIFFERENTIALLY EXPRESSED DURING DEVELOPMENT AND STRESS
    Plant journal
    
    M. Lopezmeyer e C.L. Nessler, "TRYPTOPHAN DECARBOXYLASE IS ENCODED BY 2 AUTONOMOUSLY REGULATED GENESIN CAMPTOTHECA-ACUMINATA WHICH ARE DIFFERENTIALLY EXPRESSED DURING DEVELOPMENT AND STRESS", Plant journal, 11(6), 1997, pp. 1167-1175
88. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; RICHMOND L; LUO XL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
    EFFICACY OF ORAL IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS
    Anti-cancer drugs
    
    J. Thompson et al., "EFFICACY OF ORAL IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS", Anti-cancer drugs, 8(4), 1997, pp. 313-322
89. FUKUOKA K; ADACHI J; NISHIO K; ARIOKA H; KUROKAWA H; FUKUMOTO H; ISHIDA T; NOMOTO T; YOKOTE H; TOMONARI A; NARITA N; YOKOTA J; SAIJO N
    P16(INK4) EXPRESSION IS ASSOCIATED WITH THE INCREASED SENSITIVITY OF HUMAN NONSMALL CELL LUNG-CANCER CELLS TO DNA TOPOISOMERASE-I INHIBITORS
    Japanese journal of cancer research
    
    K. Fukuoka et al., "P16(INK4) EXPRESSION IS ASSOCIATED WITH THE INCREASED SENSITIVITY OF HUMAN NONSMALL CELL LUNG-CANCER CELLS TO DNA TOPOISOMERASE-I INHIBITORS", Japanese journal of cancer research, 88(10), 1997, pp. 1009-1016
90. KANTARJIAN HM; OBRIEN SM; KEATING M; BERAN M; ESTEY E; GIRALT S; KORNBLAU S; RIOS MB; DEVOS D; TALPAZ M
    RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA
    Leukemia
    
    H.M. Kantarjian et al., "RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA", Leukemia, 11(10), 1997, pp. 1617-1620
91. HUININK WTB; GORE M; CARMICHAEL J; GORDON A; MALFETANO J; HUDSON I; BROOM C; SCARABELLI C; DAVIDSON N; SPANCZYNSKI M; BOLIS G; MALMSTROM H; COLEMAN R; FIELDS SC; HERON JF
    TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER
    Journal of clinical oncology
    
    W.T.B. Huinink et al., "TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER", Journal of clinical oncology, 15(6), 1997, pp. 2183-2193
92. TAKIMOTO CH; DAHUT W; MARINO MT; NAKASHIMA H; LIANG MD; HAROLD N; LIEBERMAN R; ARBUCK SG; BAND RA; CHEN AP; HAMILTON JM; CANTILENA LR; ALLEGRA CJ; GREM JL
    PHARMACODYNAMICS AND PHARMACOKINETICS OF A 72-HOUR INFUSION OF 9-AMINOCAMPTOTHECIN IN ADULT CANCER-PATIENTS
    Journal of clinical oncology
    
    C.H. Takimoto et al., "PHARMACODYNAMICS AND PHARMACOKINETICS OF A 72-HOUR INFUSION OF 9-AMINOCAMPTOTHECIN IN ADULT CANCER-PATIENTS", Journal of clinical oncology, 15(4), 1997, pp. 1492-1501
93. DAVIES BE; MINTHORN EA; DENNIS MJ; ROSING H; BEIJNEN JH
    THE PHARMACOKINETICS OF TOPOTECAN AND ITS CARBOXYLATE FORM FOLLOWING SEPARATE INTRAVENOUS ADMINISTRATION TO THE DOG
    Pharmaceutical research
    
    B.E. Davies et al., "THE PHARMACOKINETICS OF TOPOTECAN AND ITS CARBOXYLATE FORM FOLLOWING SEPARATE INTRAVENOUS ADMINISTRATION TO THE DOG", Pharmaceutical research, 14(10), 1997, pp. 1461-1465
94. ROSING H; HERBEN VMM; VANGORTELVANZOMEREN DM; HOP E; VANDENBOSCH JJK; HUININK WWTB; BEIJNEN JH
    ISOLATION AND STRUCTURAL CONFIRMATION OF N-DESMETHYL TOPOTECAN, A METABOLITE OF TOPOTECAN
    Cancer chemotherapy and pharmacology
    
    H. Rosing et al., "ISOLATION AND STRUCTURAL CONFIRMATION OF N-DESMETHYL TOPOTECAN, A METABOLITE OF TOPOTECAN", Cancer chemotherapy and pharmacology, 39(6), 1997, pp. 498-504
95. ERICKSONMILLER CL; MAY RD; TOMASZEWSKI J; OSBORN B; MURPHY MJ; PAGE JG; PARCHMENT RE
    DIFFERENTIAL TOXICITY OF CAMPTOTHECIN, TOPOTECAN AND 9-AMINOCAMPTOTHECIN TO HUMAN, CANINE, AND MURINE MYELOID PROGENITORS (CFU-GM) IN-VITRO
    Cancer chemotherapy and pharmacology
    
    C.L. Ericksonmiller et al., "DIFFERENTIAL TOXICITY OF CAMPTOTHECIN, TOPOTECAN AND 9-AMINOCAMPTOTHECIN TO HUMAN, CANINE, AND MURINE MYELOID PROGENITORS (CFU-GM) IN-VITRO", Cancer chemotherapy and pharmacology, 39(5), 1997, pp. 467-472
96. COGNETTI F
    TOPOTECAN, A NEW DRUG FOR THE TREATMENT O F OVARIAN-CANCER AND SMALL-CELL LUNG-CANCER - SATELLITE SYMPOSIUM OF OCTOBER 4, 1997 - 15TH NATIONAL MEETING ON EXPERIMENTAL AND CLINICAL ONCOLOGY - CHIA-DOMUS-DE-MARIA (CAGLIARI), OCTOBER 4-7, 1997 - INTRODUCTION
    Tumori
    
    F. Cognetti, "TOPOTECAN, A NEW DRUG FOR THE TREATMENT O F OVARIAN-CANCER AND SMALL-CELL LUNG-CANCER - SATELLITE SYMPOSIUM OF OCTOBER 4, 1997 - 15TH NATIONAL MEETING ON EXPERIMENTAL AND CLINICAL ONCOLOGY - CHIA-DOMUS-DE-MARIA (CAGLIARI), OCTOBER 4-7, 1997 - INTRODUCTION", Tumori, 83(6), 1997, pp. 1-2
97. SCARFONE G; VILLA A; MORANA S
    TOPOTECAN, A NEW DRUG FOR THE TREATMENT O F EPITHELIAL OVARIAN-CANCER
    Tumori
    
    G. Scarfone et al., "TOPOTECAN, A NEW DRUG FOR THE TREATMENT O F EPITHELIAL OVARIAN-CANCER", Tumori, 83(6), 1997, pp. 11-14
98. MALDONADOMENDOZA IE; VINCENT RM; NESSLER CL
    MOLECULAR CHARACTERIZATION OF 3 DIFFERENTIALLY EXPRESSED MEMBERS OF THE CAMPTOTHECA-ACUMINATA 3-HYDROXY-3-METHYLGLUTARYL COA-REDUCTASE (HMGR) GENE FAMILY
    Plant molecular biology
    
    I.E. Maldonadomendoza et al., "MOLECULAR CHARACTERIZATION OF 3 DIFFERENTIALLY EXPRESSED MEMBERS OF THE CAMPTOTHECA-ACUMINATA 3-HYDROXY-3-METHYLGLUTARYL COA-REDUCTASE (HMGR) GENE FAMILY", Plant molecular biology, 34(5), 1997, pp. 781-790
99. VINCENT RM; LOPEZMEYER M; MCKNIGHT TD; NESSLER CL
    SUSTAINED HARVEST OF CAMPTOTHECIN FROM THE LEAVES OF CAMPTOTHECA-ACUMINATA
    Journal of natural products
    
    R.M. Vincent et al., "SUSTAINED HARVEST OF CAMPTOTHECIN FROM THE LEAVES OF CAMPTOTHECA-ACUMINATA", Journal of natural products, 60(6), 1997, pp. 618-619
100. KUEFER MU; MOINUDDIN M; HEIDEMAN RL; LUSTIG RH; ROSE SR; BURSTEIN S; VANMIDDLESWORTH L; FLEMING I; JENKINS JJ; SHEARER PD
     PAPILLARY THYROID-CARCINOMA - DEMOGRAPHICS, TREATMENT, AND OUTCOME IN11 PEDIATRIC-PATIENTS TREATED AT A SINGLE INSTITUTION
     Medical and pediatric oncology
     
     M.U. Kuefer et al., "PAPILLARY THYROID-CARCINOMA - DEMOGRAPHICS, TREATMENT, AND OUTCOME IN11 PEDIATRIC-PATIENTS TREATED AT A SINGLE INSTITUTION", Medical and pediatric oncology, 28(6), 1997, pp. 433-440